Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
145.61
+1.83 (1.27%)
At close: Jul 19, 2024, 4:00 PM
145.60
-0.01 (-0.01%)
Pre-market: Jul 22, 2024, 5:31 AM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for SRPT stock have an average target of 187, with a low estimate of 109 and a high estimate of 230. The average target predicts an increase of 28.43% from the current stock price of 145.61.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SRPT stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 5 | 5 |
| Buy | 9 | 8 | 8 | 7 | 9 | 9 |
| Hold | 3 | 3 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 18 | 18 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $205 | Buy | Maintains | $205 | +40.79% | Jul 1, 2024 |
| Needham | Needham | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jun 27, 2024 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $172 → $176 | Strong Buy → Hold | Downgrades | $172 → $176 | +20.87% | Jun 26, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $165 → $200 | Buy | Maintains | $165 → $200 | +37.35% | Jun 24, 2024 |
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $139 → $185 | Hold | Maintains | $139 → $185 | +27.05% | Jun 24, 2024 |
Financial Forecast
Revenue This Year
1.98B
from 1.24B
Increased by 59.17%
Revenue Next Year
2.99B
from 1.98B
Increased by 50.88%
EPS This Year
4.06
from -5.80
EPS Next Year
11.93
from 4.06
Increased by 193.51%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.5B | 4.6B | 5.5B | 5.1B | 4.9B |
| Avg | 2.0B | 3.0B | 3.5B | 3.7B | 4.0B |
| Low | 1.6B | 1.8B | 1.6B | 2.4B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 104.0% | 133.4% | 84.0% | 46.3% | 34.6% |
| Avg | 59.2% | 50.9% | 17.6% | 4.7% | 8.4% |
| Low | 31.1% | -10.7% | -45.1% | -32.2% | -25.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.62 | 26.62 | 29.68 | 16.68 | 19.37 |
| Avg | 4.06 | 11.93 | 13.82 | 11.70 | 13.87 |
| Low | 0.88 | 1.30 | 0.74 | 5.92 | 9.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 554.8% | 148.8% | 20.7% | 65.5% |
| Avg | - | 193.5% | 15.8% | -15.3% | 18.5% |
| Low | - | -67.9% | -93.8% | -57.2% | -17.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.